93.53
2.96 (3.27%)
| Previous Close | 90.57 |
| Open | 91.39 |
| Volume | 757,736 |
| Avg. Volume (3M) | 1,530,346 |
| Market Cap | 4,576,601,088 |
| Price / Book | 78.90 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2026 |
| Diluted EPS (TTM) | -3.05 |
| Total Debt/Equity (MRQ) | 113.89% |
| Current Ratio (MRQ) | 6.61 |
| Operating Cash Flow (TTM) | -102.25 M |
| Levered Free Cash Flow (TTM) | -62.83 M |
| Return on Assets (TTM) | -39.04% |
| Return on Equity (TTM) | -115.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Celcuity Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -1.0 |
| Average | 0.63 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 13.21% |
| % Held by Institutions | 81.78% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HAHNE VICKY | 92.00 | - | 16,000 | 1,472,000 |
| LAING LANCE G. | 92.00 | - | 20,000 | 1,840,000 |
| SULLIVAN BRIAN F. | 92.00 | - | 80,000 | 7,360,000 |
| Aggregate Net Quantity | 116,000 | |||
| Aggregate Net Value ($) | 10,672,000 | |||
| Aggregate Avg. Buy ($) | 92.00 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HAHNE VICKY | Officer | 14 Aug 2026 | Acquired (+) | 16,000 | 92.00 | 1,472,000 |
| SULLIVAN BRIAN F. | Officer | 14 Aug 2026 | Acquired (+) | 80,000 | 92.00 | 7,360,000 |
| LAING LANCE G. | Officer | 14 Aug 2026 | Acquired (+) | 20,000 | 92.00 | 1,840,000 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |